---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-000540"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T14:50:43.809804+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Sunshine Biopharma appoints new COO and Chief Development Officer at annual meeting

## Summary
- Marc Beaudoin appointed COO; Malek Chamoun appointed Chief Development Officer, effective Jan 25, 2024.
- Dr. Abderrazzak Merzouki moved from COO to Chief Science Officer.
- Camille Sebaaly continues as CFO/Secretary; Dr. Steve Slilaty continues as President/CEO.
- Malek Chamoun is also President of subsidiary Nora Pharma Inc., acquired in Oct 2022.
- Beaudoin has 10 years at Sandoz Canada; Chamoun is a CPA with HEC Montreal degree.

## SEC filing metadata
- accession: 0001683168-24-000540
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316824000540/0001683168-24-000540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316824000540/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-000540
- JSON: https://secwatch.observer/filing/0001683168-24-000540.json
- Plain text: https://secwatch.observer/filing/0001683168-24-000540.txt

## Key facts
- Executive change
  Dr. Abderrazzak Merzouki was elected as Chief Science Officer at Sunshine Biopharma Inc..
  - Action: elected
  - Role: Chief Science Officer
  source text: Previously, Dr. Merzouki had held the position of Chief Operating Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316824000540/0001683168-24-000540-index.htm
- Executive change
  Malek Chamoun was appointed as Chief Development Officer at Sunshine Biopharma Inc..
  - Action: appointed
  - Role: Chief Development Officer
  source text: Malek Chamoun, age 39 , was appointed as our Chief Development Officer in January 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316824000540/0001683168-24-000540-index.htm
- Executive change
  Marc Beaudoin was appointed as Chief Operating Officer at Sunshine Biopharma Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: Marc Beaudoin, age 57, was appointed as our Chief Operating Officer in January 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1402328/000168316824000540/0001683168-24-000540-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.